| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
22051 |
| Drug |
Rimegepant |
| Brand |
Vydura® |
| Indication |
For the acute treatment of migraine with or without aura in adults; and for the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month. |
| Rapid review commissioned |
13/07/2022 |
| Rapid review completed |
12/09/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of rimegepant (Vydura®) compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
28/09/2022 |
| Pre-submission consultation with Applicant |
10/11/2022 |
| Full submission received from Applicant |
07/02/2023 |
